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Abstract
Background: Deregulation of biological pathways has been shown to be involved in the turmorigenesis of a variety of
cancers. The co-regulation of pathways in tumor and normal tissues has not been studied in a systematic manner.
Results: In this study we propose a novel statistic named AR-score (average rank based score) to measure pathway activities
based on microarray gene expression profiles. We calculate and compare the AR-scores of pathways in microarray datasets
containing expression profiles for a wide range of cancer types as well as the corresponding normal tissues. We find that
many pathways undergo significant activity changes in tumors with respect to normal tissues. AR-scores for a small subset
of pathways are capable of distinguishing tumor from normal tissues or classifying tumor subtypes. In normal tissues many
pathways are highly correlated in their activities, whereas their correlations reduce significantly in tumors and cancer cell
lines. The co-expression of genes in the same pathways was also significantly perturbed in tumors.
Conclusions: The co-regulation of genes in the same pathways and co-regulation of different pathways are significantly
perturbed in tumors versus normal tissues. Our method provides a useful tool for better understanding the mechanistic
changes in tumors, which can also be used for exploring other biological problems.
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Introduction
Cell behavior is under precise regulation by biological
pathways, which consist of a series of biochemical reactions
(metabolic pathways) or signal transduction events (regulatory
pathways) [1,2,3,4]. In normal cells, different pathways often act in
a coordinated manner for regulating biological processes.
However, in tumor cells, many important pathways are deregu-
lated and cooperation between pathways is perturbed [5]. The
involvement of specific pathways in tumorigenesis has been
investigated intensively in previous studies [6,7,8,9]. For example,
the association of the mitogen-activated protein kinase (MAPK)
signaling pathway with cancers has been reviewed in Wagner et al
[10] and in Dhillon et al [11].
Microarray experiments provide the expression levels of tens of
thousands of genes simultaneously, and have been widely used to
understand the cancer mechanisms [12]. In recent years, interest
has moved from single gene based analysis (e.g. identifying dif-
ferentially expressed genes) to gene set based analysis [13,14,15].
The goal of most gene set based methods (more specifically, the
pathway analysis) is to identify the cancer-associated pathways. This
problem has been investigated in previous studies by examining the
over-representation of pre-defined gene sets (pathways) in differen-
tially expressed genes [16], or calculating more well-defined
statistics based on gene expression profiles [17,18,19]. For instance,
one of the most popular pathway analysis methods, called gene set
enrichment analysis (GSEA) [19], calculates an enrichment score
for each pathway. This score can be regard as a weighted
Kolmogorov–Smirnov-like statistic and reflects the difference of
the pathway between two sample groups (e.g. tumor vs normal).
The statistical significance of the score is then estimated by using an
empirical phenotype-based permutation test procedure. These
methods are sensitive and powerful for identifying significant
pathways associated with cancers. However, they cannot be used to
explore the relationships between different pathways, which is also
an important issue for cancer studies.
In this study, we calculated the normalized average rank of
genes in pathways in a gene expression profile, denoted as AR-
score (average rank based score), to represent the activity of the
pathway. Similar rank-based statistics have been proposed in
previous studies [20,21], e.g. to understand microRNA regulation
in breast cancer. Since the AR-score is rank based, it is robust to
the systematic variance of samples (arising from inappropriate or
incomplete normalization) in a microarray data set. AR-scores are
thereby highly comparable between different pathways and
samples. We applied the statistic to a large number of well-
selected microarray expression data sets for normal tissues,
different types of tumors and cell lines. We calculated the AR-
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pathways [22] in these samples and found that the resulting
activity profiles are capable of distinguishing tumor/normal tissues
or classifying different tumor subtypes. Moreover, we found that
both the co-expression patterns of genes in the same pathway and
the coordination between different pathways have been deregu-
lated in tumor samples/cell-lines with respect to the normal
tissues. In practice, the method we propose here can also be
readily applied to other gene expression data for better under-
standing relevant biological problems.
Results
Calculation of AR-score for pathways
The human genome contains more than 23,000 protein-coding
genes. Their protein products are organized into a complex
network, in which they function coordinately to regulate many
important biological processes. Specifically, the network is formed
by a variety of intertwined biological pathways, which consist of a
series of chemical reactions or signal transduction events. The
activities of many pathways vary substantially among different
tissues/cell-types, and are often subjects to considerable modifica-
tions in tumors with respect to the corresponding normal tissues.
We defined a new measurement called AR-score (AS) to
quantify the activity of pathways in a biological sample based on its
gene expression profile from microarray experiment. The AR-
score for a pathway is calculated as the average rank of the relative
expression levels of all genes in this pathway normalized by the
total gene number. It takes a value from 0 to 1. A higher score
indicates that genes in the pathway are overall highly expressed
and therefore this pathway is highly active. The rank based score is
robust by nature and can be directly used to compare pathway
activities between different samples, even though they are not from
the same microarray dataset. Moreover, the activities of pathways
with different sizes (i.e. different in their gene numbers) are directly
comparable.
Pathway activities in human tissues
We calculated the AR-scores of 186 KEGG pathways in 79
human tissues for which the expression profiles were measured by
microarrays [23]. For each of the pathways, we obtained an
activity pattern, indicating the activities of the pathway across
these tissues. We found that the activities of many pathways varied
substantially between different tissues. For instance, the ‘‘CELL_-
CYCLE’’ pathway shows much higher activities in the tumor
samples such as colorectal adenocarcinoma (AS=0.65), B-
lymphoblast (AS=0.75) and leukemia promyelocytic hl60 cells
(AS=0.71) than in normal tissues. It also shows higher activity in
the labile cells (cells that multiply constantly throughout life) such
as CD71+ early erythroid bone marrow cells (AS=0.74) than the
quiescent cells such as cerebellum cells (AS=0.35). Moreover, in
fetal tissues the ‘‘CELL_CYCLE’’ pathway often shows higher
activity than the corresponding adult tissues (e.g. AS=0.65 in fetal
liver, while AS=0.38 in adult liver). These results were consistent
with the functions of ‘‘Cell_Cycle’’ pathway genes in regulation of
mitotic cell division: they are more highly expressed in tissue/cells
with more active cell division.
On the other hand, the scores for the 186 KEGG pathways in a
tissue give rise to an activity profile of the tissue. The pathway
activity profile characterizes a tissue and can be used to investigate
the similarity of different tissues in their metabolic/regulatory
states. We performed the hierarchical clustering analysis for the 79
human tissues based on their pathway activity profiles. As shown
in Figure 1, tissue/cells with relevant tissue origins are grouped
into the same cluster (e.g. the blood cell cluster and the neuron cell
cluster), suggesting that they have similar biological characteristics.
Tumor tissues or cell lines form another cluster, indicating that
they share common metabolic changes with respect to normal
tissues (e.g. enhanced activity of ‘‘CELL_CYCLE’’ pathway).
Coupling of different pathways in normal tissues
As the components of a whole network, different pathways often
function in a coordinated manner to participate in many critical
biological processes. To understand the inter-relationships among
the KEGG pathways, we calculated the correlations of their
activity profiles across the normal human tissues based on the
dataset by Su et al [23]. We noted that many pathways overlapped
in their gene members, which might lead to artificial positive
correlations in their activity profiles. To overcome this problem,
we excluded the shared genes between two pathways for their
activity profile calculation and then calculated the correlation of
the resulted activity profiles.
Our results indicated that the pathways were highly correlated
in their activity in normal tissues. Among the 17,205 possible
pathway pairs, 809 have a Spearman correlation coefficient $0.6
and 221 have a correlation #20.6, corresponding to a P2value
#10
28 (see Table S1 for all of the correlations). Figure 2 shows the
correlation network of the 186 KEGG pathways using a more
stringent cut-off value (|r|.0.75, P=2610
214). As shown, many
pathways were positively correlated in their activity profiles (red
edges), namely they are presumably coupled with each other. For
example, the activity profile of the ‘‘CELL_CYCLE’’ pathway is
positively correlated with those of the ‘‘DNA_REPLICATION’’,
the ‘‘MISMATCH_REPAIR’’, the ‘‘NUCLEOTIDE_EXCI-
SION_REPAIR’’ and 4 other KEGG pathways. More interest-
ingly, we found that the ‘‘CITRATE_CYCLE_TCA_CYCLE’’
pathway was highly correlated with the ‘‘PARKINSONS_
DISEASE’’, ‘‘ALZHEIMERS_DISEASE’’ and ‘‘HUNTING-
TONS_DISEASE’’ pathways. The high correlation of the pathway
activity profiles indicated that different pathways were coupled with
one another to achieve normal biological processes.
Pathways with different AR-scores between normal
tissues and tumors
To investigate the pathway modifications in tumor cells, we
applied the pathway analysis to 9 cancer microarray data sets,
representing 7 different cancer types: liver, lung, kidney, pancreas,
prostate, stomach and thyroid cancers (see Table S2 for
information about these data sets). For two of the cancer types
(kidney and pancreas), we collected two independent data sets.
These 9 data sets were carefully selected, each containing $15
tumor samples and $15 matched normal tissue samples. For each
data set, we calculated the AR-scores of the 186 KEGG pathways
in each of the samples, and then compared the AR-scores between
the tumor samples and the normal tissues using the t2test. Figure 3
demonstrates the differential activities of these pathways in the 9
data sets, with red and blue representing pathways that show
significantly higher activity in tumors and in normal tissues,
respectively. For example, among the 186 KEGG pathways, 69
showed significantly higher activities in kidney cancer and 55
showed significantly higher activities in normal kidney samples
(P,0.001) based on the ‘‘Kidney_Jones’’ data set. Thus, in kidney
cancer the activities of a large fraction of the KEGG pathways
(,65%) are significantly affected, indicating substantial metabolic
and regulatory modifications in tumor cells. We noted that the
sensitivity of detecting pathway activity changes in cancer depends
on the sample size of the microarray data sets. Thus, the number
of differential pathways in the 9 data sets might not be directly
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different data sets for the same cancer type, e.g. the ‘‘Kidney_
Dalgleish’’ and ‘‘Kidney_Jones’’. Detailed information about
differential pathways for each of the 9 data sets can be found in
Table S3.
AR-scores of pathways distinguish tumor and normal
tissues
Given the substantial difference in the activities of many
pathways between tumor and normal tissues, we then examined
the effectiveness of classifying normal and tumor samples based on
their activity profiles. Here we used the ‘‘Liver_Tsuchiya’’ data set
as the example. The data set contained the expression profiles for
43 tumor and 44 non-tumor liver tissues surgically resected from
patients with HCV-associated hepatocellular carcinoma. We
established a support vector machine (SVM) to classify the tumor
and non-tumor samples using the activity profiles for KEGG
pathways as the classifiers, and examined the accuracy of the
model based on the leave-one-out cross-validation method (see
‘‘Method and Materials’’ for details). When 62 pathways with
significant activities between tumor and non-tumor samples
(P,10
25) were used as the classifiers, the SVM model achieved
95% accuracy (83 out of the 87 samples). The same accuracy was
obtained when the 11 most significant pathways were used
(P,10
210). Impressively, a SVM model based on only 5 pathways
(P,10
212) could still result in correct classification for 82 samples
(94%). In contrast, the average classification accuracy was 0.85
when 5 randomly selected pathways were used as the classifiers.
The classification power of these 5 pathways is also shown Figure 4:
a simple hierarchical clustering analysis can roughly separate
samples into tumor and normal groups. These results indicated
that the activity profiles of KEGG pathways were highly
informative for distinguishing tumor tissues from the normal
tissues.
Figure 1. Hierarchical clustering of 79 human tissues based on their activity profiles. For each sample, the activity profile consists of the
AR-scores for 186 KEGG pathways. The two lines mark the cancer cluster (left) and neuron cell cluster (right). The details are accessible in high-
resolution images linked from the website.
doi:10.1371/journal.pone.0027579.g001
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subtypes based on the pathway activity profiles. As an example,
we applied the SVM method to classify estrogen receptor positive
(ER+) and negative (ER2) samples in the breast cancer data [24],
which contained the expression profiles for 53 ER+ and 44 ER-
breast cancer samples. The SVM method achieved 86%
classification accuracy (83 out of 97 samples) when 65 most
significant pathways (P,0.01) were used. Even when we reduced
the number of pathways into 10 (P,10
25), the model still gave rise
to a classification accuracy of 85% (83 out of 97 samples). The
hierarchical clustering results based on these 10 pathways were
shown in Figure 5. Thus, the activity profiles of pathways were
capable of discriminating the subtypes of cancers.
We also examined the capability of the pathway activity profiles
for predicting prognosis. In the breast cancer data from van’t Veer
et al [24], the disease free survival (DFS) times for patients were
available. We divided the patients into two groups based their DFS
times: good-prognosis group (DFS$60 month) and poor-prognosis
group (DFS,60 month). We identified 5 pathways that showed
significant activities between the two groups (P,0.001) and used
them as the classifiers for the SVM model. Our model correctly
classified 70 out of the 98 patients (71%). A logistic regression
model based on expression levels of 70 genes instead achieves a
prediction accuracy rate of 83% [24]. Despite the much decrease
in classification accuracy, our results indicated that the pathway
activity profiles were, to some extent, useful for predicting
prognostic outcomes of cancer patients.
Gene-based classification of tumors has been intensively
described in previous studies [24,25]. Since the AR-score of a
pathway summarizes the expression changes of all genes, we would
expect more consistent results for different datasets of the same
cancer type at the pathway level than at the gene level. Therefore,
in comparison with genes, pathways are more stable classifiers for
distinguish sample classes. For example, we examined the
classification accuracies of 10 pathways and 20 genes in two
independent kidney cancer data, the Dalgliesh data and the Jones
data. These pathways and genes were the most differential ones
between the cancer and the normal kidney samples in the
Dalgliesh data [26]. In the same data, out of 160 samples a SVM
model correctly classified 153 samples (96%) based on the 10
pathways, and 158 samples (99%) based on the 20 genes. In
contrast, when applied to the Jones data, the pathway-based
model still achieved high accuracy (86 out of 92 samples, 94%),
whereas the gene-based model dropped to 90% (83 out of 92
samples).
Reduced correlation of activity profiles between
pathways in tumors
In normal cells, behavior is regulated by a number of pathways
that cross-talk and are highly coordinated with each other.
Cancer, in many ways, can be regarded as a disease of mis-
regulated signal transduction. Thus, we would expect to see the
decoupling of pathways in cancer with respect to normal cells. To
investigate this issue, we carefully selected five microarray gene
expression data sets, three for normal tissues (contain expression
profiles for 73, 353 and 36 normal tissues, respectively) [23,27,28],
one for cancers (contains 341 expression profiles for 6 different
cancer types) [29], and one for NCI-60 cell lines (contains
Figure 2. Correlation network of the KEGG pathways. Each node represents a KEGG pathway. The pathways that are positively (.0.75) or
negatively (,20.75) correlated are connected by "red" and "green" edges, respectively. The size of a node indicates the number of genes in the
corresponding pathway. The details are accessible in high-resolution images linked from the website.
doi:10.1371/journal.pone.0027579.g002
Analysis Reveals Deregulation of Pathways
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27579expression profiles for 60 tumor cell lines) [30]. These data sets
represented a variety of normal tissues, tumor samples, or cell
lines. In comparison with datasets containing only a single normal
or tumor tissue type, these data sets carried more biological
variations and therefore were more suitable for correlation
analysis.
We calculated the Spearman correlation coefficients for all pairs
of the 186 KEGG pathways in the 5 data sets. Our results showed
that the activity profiles of pathways were more correlated (either
positively or negatively) in the normal data sets (Normal_Su,
Normal_Roth, and Normal_Ge) than in the tumor and the NCI-
60 data sets (NCI-60). Figure 6 shows the correlation patterns of
the pathway activity profiles in Norml_Roth and the NCI-60 data
sets (see Figure S1 for correlation patterns in all of the five data
sets). Apparently, the pathways were decoupled in tumor samples
and cell lines with respect to the normal tissues. Furthermore, the
Figure 3. Pathways with differential activities between tumor samples and the corresponding normal tissues. The activity difference of
a pathway in tumor and normal tissues was examined by the t2test and 2log10(P2value) was color coded. Red indicates higher activity in tumors,
and blue indicates higher activity in normal tissues. The results for 9 tumor/normal data sets are shown, representing 7 different cancer types.
doi:10.1371/journal.pone.0027579.g003
Figure 4. Hierarchical clustering of heptocellular carcinoma and normal liver samples based on the AR-scores for 5 pathways.
doi:10.1371/journal.pone.0027579.g004
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pathway pairs in the normal data sets were significantly higher
than those in the tumor data set and the NCI-60 cell line data:
Normal_Su vs. tumor (t2score=58), Normal_Su vs. NCI-60
(t2score=61), Normal_Roth vs. tumor (t2score=69), Normal_
Roth vs. NCI-60 (t2score=72), Normal_Ge vs. tumor
(t2score=45) and Normal_Ge vs. NCI-60 (t2score=47), all
corresponding to a very significant P2value (P,10
2308). In
addition, we examined the correlations of pathways in tumor and
normal samples from the same dataset (see the 9 datasets described
in Section ‘‘Pathways with different AR-scores between normal
tissues and tumors’’), which confirmed the conclusion that
pathways were more correlated in normal tissues than in can-
cers. For example in the ‘‘Kidney_Dalgliesh’’ data, correlations
(absolute values) between pathways are significantly higher in
kidney cancers than in the normal kidney controls (t2score=46,
P,10
2308).
Reduced correlation of expression profiles for genes from
the same pathway in tumors
We have shown that the correlations of activity profiles between
the pathways were reduced significantly in tumor samples or cell
lines. We then asked: do the correlations of the expression profiles
for genes in the same pathway also reduced in tumors? For each
pathway we calculated the Spearman correlation coefficients for
all gene pairs in the three normal data sets as well as in the tumor
and NCI-60 data sets. The average of these pairwise correlations
was then computed to represent the co-regulation of genes in a
pathway. As shown in Figure 7, the expression profiles of genes in
the same pathway were more correlated in the normal tissues than
in the tumor and the NCI-60 data sets. For example, the average
correlations of all gene pairs in the ‘‘RIBOSOME’’ pathway were
0.81, 0.76 and 0.72 in the three normal data sets, whereas the
value was 0.41 in the tumor data set and 0.48 in the NCI-60 cell
line data set (see Table S4 for the average correlations of all
pathways). The reduced co-regulation of genes within the same
pathway in tumors were further confirmed by comparing the
average correlations of all the 186 pathways using the t2test:
Normal_Su vs. tumor (P=3610
211), Normal_Su vs. NCI-60
(P=5610
218), Normal_Roth vs. tumor (P=2610
213), Normal_-
Roth vs. NCI-60 (P=2610
217), Normal_Ge vs. tumor
(P=2610
211) and Normal_Ge vs. NCI-60 (P=3610
215).
Comparison with the GSEA method
To further validate our results, we repeated the above-described
analysis using the ES scores (enrichment scores) introduced in the
GSEA method. Specifically, for each sample in a microarray data
we calculated the ES-scores of all KEGG pathways. We compared
the ES-scores of pathways in cancer versus normal samples to
identify the differentially expressed pathways using the Wilcoxon
test. The results we achieved are very consistent with those
obtained from the AR-score based analysis (note that the t2test
was used for comparing AR-scores). As an example, in the Liver
cancer data we identified 88 significant pathways based on AR-
scores and 85 significant pathways based on ES2scores
(P,0.001). Among these pathways, 64 are identified by both
methods. More importantly, among them the up-regulated and
down-regulated pathways identified by the two methods are
perfectly matched (see Table S5).
We also examined the correlation between different pathways in
normal and cancer data sets based on their ES2scores. This
analysis further validated our conclusion that the co-regulation of
pathways tended to be decoupled in cancers with respect to
normal tissues (see Figure S2). The correlation coefficients of
ES2scores of pathways in the normal data sets were significantly
higher than those in the tumor/cell-line data sets: Normal_Su vs.
tumor (t2score=32, P=10
2208), Normal_Su vs. NCI-60
(t2score=39, P,10
2308), Normal_Roth vs. tumor (t2score=41,
P,10
2308), Normal_Roth vs. NCI-60 (t2score=45, P,10
2308),
Normal_Ge vs. tumor (t2score=28, P=5610
2163) and Nor-
mal_Ge vs. NCI-60 (t2score=33, P=1610
2226).
Discussion
Previous studies have reported the association of a number of
pathways with cancers [8,9,11]. In fact, it has been shown that
Figure 5. Hierarchical clustering of ER+ and ER- breast cancer samples based on the AR-scores for 11 pathways.
doi:10.1371/journal.pone.0027579.g005
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27579Figure 6. Reduced correlations of activities between pathways in cancer cell lines respect to normal tissues. The bottom left half shows
the correlation matrix for 186 KEGG pathways in normal tissues. The top right half shows the correlation matrix for 186 KEGG pathways in NCI-60 cell
lines.
doi:10.1371/journal.pone.0027579.g006
Figure 7. Reduced correlations of expression profiles for genes in the same pathways. For each of the 186 KEGG pathways, the average
Spearman correlation coefficient was calculated across all pairs of genes in the pathway. (A) Distributions of the average correlations of the 186
pathways. (B) Average correlations of the 186 pathways in normal tissues and NCI-60 cell lines. Note most of the pathways show stronger gene co-
expression in normal tissues than in cancer cell lines.
doi:10.1371/journal.pone.0027579.g007
Analysis Reveals Deregulation of Pathways
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27579many oncogenes and tumor suppressor genes function as key
factors in specific pathways [31,32]. These studies, however, were
centered mostly on the differential expression of individual genes
or pathways. The co-expression of genes in the same pathways and
the inter-relationships between different pathways have not been
compared between tumor and normal tissues. In this study, we
systematically investigated this issue using a large number of
microarray data sets that contained expression profiles for normal
tissues, different types of cancer tissues and cell lines. In cancer
tissues and cell lines we observed the reduced correlation in
expression profiles between genes from the same pathways as well
as in activity profiles between different pathways. These results
apparently suggested the connection of de-regulation of genes and
pathways with carcinogenesis.
Several methods for pathway analysis have been previously
proposed, such as Gene Set Enrichment Analysis (GSEA) [19].
These methods can be effectively used to detect pathways
associated with cancer, but they are not designed for examining
inter-relationships between pathways. The AR-score we propose
captured the relative expression levels of genes in a pathway and
can be used for understanding the co-regulation between
pathways. As a rank based statistic, the AR-score is robust to
noise and incomplete normalization of samples, and is highly
comparable between pathways and samples. Despite of these
advantages, it also has its limitations. When a pathway is active in
a sample, we should not expect all proteins in the sample to be
highly active. Only a fraction of active proteins may be active as a
result of their functional redundancy. In a pathway, the proteins
act either as activators or repressors. For repressors in an active
pathway, we may not expect high expression of the corresponding
genes. Instead, their expression may be down-regulated to activate
a pathway. Moreover, the activities of some pathways may be
largely regulated at the post-translational levels rather than at the
mRNA level [33]. Thus the calculation of the AR-score can still be
improved by taking these issues into account. In addition, it might
also be improved by taking into account the variance of ranks of
genes in a pathway, instead of simply averaging them.
The aforementioned limitations, however, are not likely to affect
our main conclusions. Although genes in a pathway could be
either up- or down- regulated in cancer versus normal, our results
suggest that they tend to be regulated into the same direction.
First, genes in the same pathway are more likely to be positively
correlated in their expression profiles, which is particularly true in
normal tissues (Figure 7). Second, for many pathways up- or
down-regulated genes are predominant in the differentially
expressed genes between tumor and normal. As an example, we
counted the fraction of genes that were up-regulated in kidney
cancer with respect to normal kidneys (Dalgliesh data), and found
that in 56 out of 186 KEGG pathways $90% differentially
expressed genes were actually up-regulated (Table S6). Third, the
relative expression levels of genes were measured in Van’t Veer’s
breast cancer data (log ratios from the two-channel arrays), for
which positive and negative values indicate up- and down-
regulation, respectively. We examined the results of using a
modified way to calculate the AR-scores of pathways. Namely, we
ranked genes based on the ‘‘absolute’’ rather than the original
values of their expression levels (log ratios). In this way, both the
up- and down- regulated genes were taken into account, instead of
canceling out with each other. Analysis based on the modified AR-
scores again indicates perturbed co-expression of genes in the same
pathway as well as perturbed co-regulation between different
pathways in breast cancer with respect to normal tissues.
During human tumor development, the tumor cells have to
obtain several capabilities, such as sustaining proliferative signaling
and resisting cell death (Hanahan et al. 2001). Acquirement of
these capabilities is often involved in the de-regulation of related
pathways such as the apoptosis pathway. To de-regulate a
pathway, the expression of a different subset of its genes might
be perturbed in different tumor samples even for the same type of
cancer. For this reason, the alteration of pathways is often more
consistent than that of genes in tumor samples of the same type.
For example, we compared the differentiation of pathways and
genes between tumor and normal samples in two independent
kidney cancer data sets. Specifically, the t-scores were calculated
by comparing the AR-scores of pathways or expression levels of
genes in tumors versus normal. The t-scores for pathways are more
correlated (R=0.81) between the two data sets than those for
genes (R=0.42), indicating high consistency between tumor
samples at the pathway level. Such a consistency is only valid
for those well-defined biological pathways, not for the random
gene sets, which are mechanistically less informative. We
examined the classification power of a number of random gene
sets that are significantly different between tumor and normal
samples. These random gene sets resulted in a classification
accuracy (driven by several differentially expressed genes) that is
only slightly lower than that of the real pathways. When applied to
another data set, these gene sets are no longer effective for
classification.
In brief, we propose a statistic to measure the pathway activities
in gene expression profiles. We applied the method to a large
number of microarray gene expression data sets to investigate
changes of pathways in their activities and relationships in cancers
with respect to normal tissues. We found that the AR-score we
defined is capable of classifying samples into biological meaningful
groups, e.g. normal vs tumor liver, and ER+ vs ER- breast cancer
subgroups. We also found that in tumor samples and cell lines, the
co-regulation of genes in the same pathways and between
pathways was significantly perturbed with respect to normal
tissues. More intensive investigation of the relationship changes
between pathways would be helpful for further understanding the
mechanisms of carcinogenesis.
Materials and Methods
Microarray gene expression data sets
A total of 14 microarray data sets were used in this study,
among which three are for normal tissues, one is for cancer cell
lines and ten are for tumor/normal samples. The breast cancer
data was from van’t Veer et al [24], whereas the others were
downloaded from the (GEO) database [34]. The accession IDs for
normal tissues are GSE1133 by Su et al [23], GSE3526 by Roth et
al [27], and GSE2361 by Ge et al [28]. The accession ID for the
NCI-60 cell line data set is GSE5720 [30]. The accession IDs for
the tumor/normal samples are GSE17895 and GSE15641 for
kidney cancer [26,35], GSE17856 for liver cancer [36],
GSE12771 for lung cancer [36], GSE15471 and GSE16515 for
pancreas cancer [37,38], GSE6919 for prostate cancer [39],
GSE13911 for stomach cancer [40], as well as GSE5364 for
thyroid cancer [29]. All of these tumor/normal data sets contain
gene expression profiles for $15 tumor samples and $15
corresponding normal tissue samples.
Gene set information of pathways
The pathway information was downloaded from the database
called Kyoto Encyclopedia of Genes and Genomes (KEGG) at
http://www.genome.jp/kegg/ [22], where gene products were
structured into 186 metabolic or signaling pathways.
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Except for the breast cancer data from [24]and the liver cancer
data from [36], the majority of gene expression data used in this
work are performed using one-channel arrays. In these data, the
absolute expression values of genes are measured. For each
dataset, we performed gene-wise standardization by subtracting
the mean and then dividing by the standard deviation of
expression values of a gene in all samples. This step converts the
expression of genes from absolute values into relative levels, which
reflect their expressional variation in different samples. For the
breast cancer and the liver cancer data, gene-wise standardization
was not required, since gene expression in these two datasets was
measured by two-channel arrays and represented originally as the
relative values.
Calculation of AR-score for pathways
Given the expression profile for a specific biological sample, we
first sorted the expression levels for all genes in decreasing order.
Then, we calculated the AR-score of a pathway by averaging the
ranks of all genes in this pathway and then normalizing the result
with the total gene numbers in the expression profile. Namely,
AR{score~
P m
i~1
ri
m.n
, where ri is the rank of the ith in the pathway,
m is the number of genes in this pathway and n is total number of
genes in the gene expression profile. The AR-score takes a value
within (0,1), with a larger value indicating relatively higher
expression levels of genes in a pathway and therefore a higher
pathway activity.
Correlation of activity profiles between pathways
The co-regulation of two pathways can be inferred based on the
similarity of their activity profiles- their AR-scores in all of the
samples. Simply, the Spearman Correlation Coefficient (r)
between the activity profiles of two pathways can be used to
measure the similarity. However, this would over-estimate the
correlation if two pathways share common genes. To overcome
this problem, we first removed genes shared by two pathways and
calculated their AR-scores based on the remaining unique ones.
The resulting AR-score profiles were subsequently used for
estimating the correlation between the two pathways. Denote
{xi, i=1,2, …, p} and {yi, i=1,2, …, p} as the rank vectors (p is
the number of samples) for the AR-scores of two pathways, the co-
regulation is calculated as
rx,y~
X
i xi{x ðÞ yi{y ðÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ X
i xi{x ðÞ
2 X
i yi{y ðÞ
2
q
.
Construction of correlation networks for pathways
We calculated the Spearman Correlation Coefficient for all
possible pairs of the 186 KEGG pathways, while taking into
account the shared genes between them (see Section ‘‘Correlation
of activity profiles between pathways’’). A total of 17,205
correlations were calculated, among which we observed much
more positively correlated pathway pairs than negatively correlat-
ed ones. We then set |r|.0.75 as the cut-off value for correlations
to select pathway pairs with similar AR-score profiles. Finally, all
the pathways with |r|.0.75 were connected to form a co-
regulation network for the pathways. The network contains both
positive (correlated pathways) and negative (anti-correlated
pathways) interactions. In normal tissues (Normal_Su), the above
analysis resulted in a network with 59 nodes (pathways) and 127
edges (co-regulation relationships, |r|.0.75), among which 110
are positive correlations and 17 are negative correlations.
Identification of differential pathways between different
sample types
We used the t2test to identify the pathways that show
differential activities between two sample groups (e.g. tumor
versus normal). For instance, to identify pathways related to lung
cancer, we compared the AR-scores of all pathways in lung tumor
samples with those in normal lung tissues using the t2test,
resulting a P2value for each pathway. To correct for multiple
testing, we calculated the corresponding Q2value (false discovery
rate, FDR) for each of the P2values using the method proposed by
Storey et al [41]. The pathways with a Q2value,0.01 (1% FDR)
were considered differential pathways between the two groups.
Hierarchical clustering of samples based on pathway
activity profiles
We performed hierarchical clustering to investigate the
similarity of normal human tissues based on the AR-scores of
the 186 KEGG pathways. Specifically, the ‘‘complete linkage’’
method was applied and the ‘‘Euclidian distance’’ was used as the
dissimilarity metric in the hierarchical clustering analysis.
Hierarchical clustering was also used to cluster tumor and normal
samples or to cluster different tumor subtypes. For this purpose, we
usually selected a number of pathways that showed differential
activities and performed hierarchical clustering based only on
these pathways. For example, Figure 5 was based on five pathways
that are most significantly different between normal liver and
heptocellular carcinoma.
Classification of samples based on pathway activity
profiles
We constructed support vector machine (SVM) models [42] to
classify different sample types. For example, we used the SVM
model to classify estrogen receptor positive (ER+) versus estrogen
receptor negative (ER2) based on the AR-scores of the five most
significant pathways. The classification accuracy was estimated by
using leave-one-out cross-validation method. Each time a single
sample was left out and the SVM mode was trained based on the
remaining samples. The trained model was then used to predict
the estrogen receptor (ER) status of the sample being left out. This
procedure was repeated until each sample was left out once and
we finally compared the predictions with the actual ER status to
estimate the prediction accuracy of the classification model.
The SVM models were also used to classify normal versus
tumor samples, and to predict the clinical outcome (good- or poor-
prognosis groups) of patients.
Correlation of expression profiles of genes in the same
pathway
We calculated the Spearman correlation coefficient of the
expression profiles for all possible pairs of genes in the same
pathway. Then these correlations were averaged to represent the
strength of co-expression of genes in this pathway. The average
correlations were calculated for all of the 186 KEGG pathways.
The average correlations for most pathways are positive values,
particularly in normal tissues, indicating that genes in the same
pathway tend to be co-expressed.
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To confirm our findings using the AR-score based method, we
also performed all analysis using the statistic, ‘‘enrichment score’’
(ES), proposed by the GSEA method [19]. GSEA examines the
distribution of genes in a gene set in a ranked gene list, which is
sorted based on the correlations of genes with an interested
phenotype. When applied to the case-control microarray data,
GSEA is typically used to calculate the ES-scores for gene sets based
on class comparison, e.g. the t-scores of genes in tumor versus
normal. For comparison purposes, inthis work we calculatedthe ES
scores of the KEGG pathways in each relative expression profiles of
a dataset, as we did for the AR-scores. The ES-score measures the
maximum deviation between two cumulative distribution functions,
and typically follows a bimodal distribution. In contrast, the AR-
score is normalized average ranks of genes, which follows
approximately a normal distribution (see Figure S3). Such a
favorable feature of AR-score facilitates the subsequent downstream
analysis, e.g. calculating correlation coefficient and comparing
scores between sample classes using t2test, etc.
All the calculation described above was performed using the R
language and packages available from http://www.r-project.org.
Supporting Information
Figure S1 Correlation patterns of pathway activities (AR-scores)
in five microarray data sets. The figure shows pairwise correlations
of all pathways in three normal tissue data sets, one multiple-
tumor data set and one NCI-60 cell line data set.
(PDF)
Figure S2 Correlation patterns of pathway activities (ES-scores)
in five microarray data sets. The figure shows pairwise correlations
of all pathways in three normal tissue data sets, one multiple-
tumor data set and one NCI-60 cell line data set. Note that ES-
scores are used to represent the pathway activities, whereas in
Figure S1 AR-scores are used.
(PDF)
Figure S3 Distribution of AR-scores and ES-scores. Distribu-
tions of the AR-scores (left panel) and ES-scores (right panel) for
pathways in Normal_Su data were shown. As shown, AR-scores
approximately follow a normal distribution, while ES-scores follow
a bimodal distribution with a positive and a negative peak.
(PDF)
Table S1 Correlations for all possible pairs of the KEGG
pathways. Spearman correlation coefficients of all the 17,205 pairs
of the 186 KEGG pathways were calculated.
(XLS)
Table S2 Information about the nine tumor vs normal data sets.
(XLS)
Table S3 Pathways showing differential activities between tumor
and normal tissues in nine data sets. T-test was used to compare
the activities of all the 186 KEGG pathways between tumor and
normal samples in nine microarray data sets.
(XLS)
Table S4 Average correlations of expression profiles across all
gene pairs in the same pathways. The table contains the average
Sperman correlation coefficients for all the 186 KEGG pathways
in three normal tissue data sets, one multiple-tumor data set and
one NCI-60 cell line data set. For each pathway, the correlations
for all possible pairs of genes in the pathway were calculated and
averaged.
(XLS)
Table S5 Comparison of the differential pathways identified by
the AR-score based and the ES-score based methods. The table
contains the pathways that show significantly activities in Liver
cancer and normal liver samples. The AR-scores of pathway in
cancer and normal are compared using the t-test, whereas the ES-
scores are compared using the Wilcoxon test. Note that pathways
identified by the two methods are highly consistent.
(XLS)
Table S6 Percentage of up-regulated genes in pathways. The
table contains the numbers of genes in each pathway, the fraction
of up-regulated genes (t-score.0) in all genes or in the
differentially expressed genes (P,0.001). Calculation is based on
the Dalgliesh kidney cancer data.
(XLS)
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